Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 2/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | VDR | P11473 | 12/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | GC | P02774 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13804815 | 1.00 | CDC25A (0.46) | CDC25ACDC25BVDRMAPTSMN1; SMN2 | |
| SCHEMBL5063778 | 1.00 | CDC25A (0.46) | CDC25ACDC25BVDRMAPTSMN1; SMN2 | |
| SCHEMBL13804829 | 1.00 | CDC25A (0.46) | CDC25ACDC25BVDRMAPTSMN1; SMN2 | |
| SCHEMBL9973371 | 1.00 | CDC25A (0.46) | CDC25ACDC25BVDRMAPTSMN1; SMN2 | |
| SCHEMBL14153825 | 1.00 | CDC25A (0.46) | CDC25ACDC25BVDRMAPTSMN1; SMN2 | |
| SCHEMBL24286115 | 1.00 | CDC25A (0.46) | CDC25ACDC25BVDRMAPTSMN1; SMN2 | |
| SCHEMBL9070760 | 1.00 | CDC25A (0.46) | CDC25ACDC25BVDRMAPTSMN1; SMN2 | |
| SCHEMBL13841866 | 1.00 | CDC25A (0.46) | CDC25ACDC25BVDRMAPTSMN1; SMN2 | |
| SCHEMBL19625105 | 1.00 | CDC25A (0.46) | CDC25ACDC25BVDRMAPTSMN1; SMN2 | |
| SCHEMBL14489129 | 0.90 | CDC25A (0.47) | CDC25ACDC25BVDRMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932595-B2 | VDR-silent vitamin D derivative as inhibitors of SREBP and pharmaceutical use thereof | KYOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY, TEIKYO UNIVERSITY and THE UNIVERSITY OF TOKYO (JP) | 2024-03-19 | — | — | US | disclosed |
| WO-2022061193-A1 | VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF | KYOTO UNIVERSITY (JP) | 2022-03-24 | — | — | WO | disclosed |
| US-20220081381-A1 | VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF | KYOTO UNIVERSITY (JP) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932595-B2 | VDR-silent vitamin D derivative as inhibitors of SREBP and pharmaceutical use thereof | VDR, CYP24A1, CYP2R1 | CDC25A 3166/4885CDC25B 3142/4885VDR 1/4885 |
| US-20220081381-A1 | VDR-SILENT VITAMIN D DERIVATIVE AS INHIBITORS OF SREBP AND PHARMACEUTICAL USE THEREOF | VDR, CYP24A1, CYP2R1 | CDC25A 3166/4885CDC25B 3142/4885VDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.